Epistaxis with MCC DRG Reimbursement & Medicare Rates

Summary & Overview

Epistaxis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

DRG 150 addresses inpatient care for epistaxis with a Major Complication or Comorbidity, encompassing cases with substantial clinical complexity and higher resource needs. Accurate assignment influences Medicare inpatient reimbursement by directing higher-weighted payment under the Diagnosis-Related Group framework.

Epistaxis with Major Complication or ComorbidityDRG Epistaxis with MCCDRG 150Diagnosis-Related GroupInpatient ReimbursementMedicareOtolaryngologyNasal HemorrhageTransfusion ManagementHospital Coding

DRG 150 Overview

DRG 150 covers inpatient admissions for epistaxis, or nosebleed, when accompanied by a Major Complication or Comorbidity that significantly increases resource use and clinical complexity. This Diagnosis-Related Group typically applies when patients require intensive interventions, transfusions, or management of significant comorbid conditions. It matters for Medicare payment because the presence of a Major Complication or Comorbidity shifts reimbursement to a higher-weighted payment tier within the Medicare Severity Diagnosis-Related Group system. Proper assignment affects hospital payment for resource-intensive epistaxis cases.

National Payment Rates

Across the commercial payers shown, negotiated rates range from about $11K to $49K, with payer medians and quartiles varying by insurer; the widest spread is between Anthem (max $49K) and BCBS (median $11K). See the table and chart below for payer-specific distributions. Payer labels use full commercial names like Blue Cross Blue Shield, UnitedHealth Group, Cigna, Aetna, and Anthem for clarity.

Mean Rates by Payer — National — DRG 150

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($12.7k), average submitted covered charges ($58.1k), average Medicare payment amount ($10.8k), and total discharges (726).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

In Alaska, DRG 150 rates span from $21K to $32K across reported payers, with Anthem and Blue Cross Blue Shield clustered at $21K and Cigna at $32K. The most notable deviation from national averages is Cigna’s rate sitting well above the state’s other payers and above several national medians. See the table and chart below for payer-level detail.

Key Insights for Alaska

Anthem is the highest-paying payer in Alaska at $21K, while BCBS (Blue Cross Blue Shield) also reports $21K and Cigna is higher at $32K; Cigna represents the highest payer in the state when compared across available payers and Anthem/BCBS the lowest.
Alaska’s payer rates range from $21K to $32K, with Cigna notably above the other state payers and exceeding typical national median levels for some payers, indicating a meaningful upward deviation versus many national benchmarks.

Clinical Trials

Acute hemostatic intervention trials: randomized or prospective studies comparing immediate bleeding-control strategies in hospitalized adults with severe epistaxis complicated by major comorbidities (for example, patients with coagulopathy, on anticoagulation, or with significant cardiovascular disease). These studies evaluate time to hemostasis, need for transfusion, procedure rates (nasal packing, cautery, arterial ligation/embolization), and short-term complications, addressing the acute management decisions that determine length of stay and resource intensity. Results inform in-hospital protocols that directly affect inpatient reimbursement and resource allocation for high-acuity DRG 150 cases.
Comparative effectiveness and care pathway research: observational cohorts and pragmatic trials comparing different care pathways (emergency department-only vs. admission with ENT consult, early interventional radiology vs. surgical approaches, protocols for reversal of anticoagulation) in heterogeneous adult populations who present with epistaxis and major complications. These studies focus on outcomes such as rates of rebleeding, procedural utilization, ICU admission, and total hospitalization cost, helping payers and hospitals identify which pathways reduce complications and avoidable use of high-cost services. Findings guide clinical pathways and case management strategies to optimize DRG payments and minimize costly readmissions or extended stays.
Post-discharge outcomes and readmission prevention studies: cohort studies and quality-improvement trials following patients discharged after hospitalization for epistaxis with significant comorbidity to assess rates and predictors of 30- and 90-day readmission, delayed bleeding, thromboembolic events after anticoagulation management changes, and health-related quality of life. These investigations often target transitional care interventions (structured follow-up, anticoagulation clinic referral, patient education) in older adults and those with bleeding diatheses, providing evidence on interventions that reduce readmissions and downstream costs. This research is relevant to providers and payers because reducing readmissions and post-discharge complications improves overall outcomes and impacts total cost of care associated with DRG 150 episodes.

Ear, Nose, Mouth and Throat Malignancy with CC: Inpatient Reimbursement Overview

145-OTHER-EAR-NOSE-MOUTH-AND-THROAT-O-R-PROCEDURES-WITHOUT-CC-MCC

Other Ear, Nose, Mouth and Throat O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

142-MAJOR-HEAD-AND-NECK-PROCEDURES-WITHOUT-CC-MCC

Major Head and Neck Procedures without CC/MCC: Inpatient Reimbursement Overview

138-MOUTH-PROCEDURES-WITHOUT-CC-MCC

Mouth Procedures without CC/MCC: Inpatient Reimbursement Overview

144-OTHER-EAR-NOSE-MOUTH-AND-THROAT-O-R-PROCEDURES-WITH-CC

Other Ear, Nose, Mouth and Throat O.R. Procedures with CC: Inpatient Reimbursement Overview

155-OTHER-EAR-NOSE-MOUTH-AND-THROAT-DIAGNOSES-WITH-CC

Other Ear, Nose, Mouth and Throat Diagnoses with CC: Inpatient Reimbursement Overview

154-OTHER-EAR-NOSE-MOUTH-AND-THROAT-DIAGNOSES-WITH-MCC

Other Ear, Nose, Mouth and Throat Diagnoses with MCC: Inpatient Reimbursement Overview

141-MAJOR-HEAD-AND-NECK-PROCEDURES-WITH-CC

Major Head and Neck Procedures with CC: Inpatient Reimbursement Overview

151-EPISTAXIS-WITHOUT-MCC

Epistaxis without MCC: Inpatient Reimbursement Overview

153-OTITIS-MEDIA-AND-URI-WITHOUT-MCC

Otitis Media and URI without MCC: Inpatient Reimbursement Overview

Showing 1–10 of 24

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$13K	$58K	$11K	730